JP2022524325A5 - - Google Patents

Info

Publication number
JP2022524325A5
JP2022524325A5 JP2021552522A JP2021552522A JP2022524325A5 JP 2022524325 A5 JP2022524325 A5 JP 2022524325A5 JP 2021552522 A JP2021552522 A JP 2021552522A JP 2021552522 A JP2021552522 A JP 2021552522A JP 2022524325 A5 JP2022524325 A5 JP 2022524325A5
Authority
JP
Japan
Prior art keywords
composition according
administration
formulated
subject
hsp60
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524325A (ja
JP7738377B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020794 external-priority patent/WO2020180865A1/en
Publication of JP2022524325A publication Critical patent/JP2022524325A/ja
Publication of JP2022524325A5 publication Critical patent/JP2022524325A5/ja
Priority to JP2025017178A priority Critical patent/JP2025087689A/ja
Application granted granted Critical
Publication of JP7738377B2 publication Critical patent/JP7738377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552522A 2019-03-04 2020-03-03 神経炎症の調節 Active JP7738377B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017178A JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813556P 2019-03-04 2019-03-04
US62/813,556 2019-03-04
PCT/US2020/020794 WO2020180865A1 (en) 2019-03-04 2020-03-03 Modulating neuroinflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017178A Division JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Publications (3)

Publication Number Publication Date
JP2022524325A JP2022524325A (ja) 2022-05-02
JP2022524325A5 true JP2022524325A5 (https=) 2023-03-10
JP7738377B2 JP7738377B2 (ja) 2025-09-12

Family

ID=72337602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552522A Active JP7738377B2 (ja) 2019-03-04 2020-03-03 神経炎症の調節
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Country Status (7)

Country Link
US (1) US20220143139A1 (https=)
EP (1) EP3934674A4 (https=)
JP (2) JP7738377B2 (https=)
KR (1) KR20210148163A (https=)
CN (1) CN113795266A (https=)
CA (1) CA3132333A1 (https=)
WO (1) WO2020180865A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118796A1 (en) 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Compositions for controlling neuronal outgrowth
KR102829678B1 (ko) * 2021-12-13 2025-07-04 차의과학대학교 산학협력단 신경전구세포를 포함하는 시신경병증의 예방 또는 치료용 약학 조성물
WO2024220474A1 (en) * 2023-04-21 2024-10-24 The Schepens Eye Research Institute, Inc. Methods of treating age-related macular degeneration targeting igfbpl-1
AU2024308069A1 (en) * 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
TR201902542T4 (tr) 2010-04-13 2019-03-21 M Lab Gmbh Glokom i̇çi̇n tani yöntemleri̇
WO2012118796A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Compositions for controlling neuronal outgrowth

Similar Documents

Publication Publication Date Title
JP2022524325A5 (https=)
Wang et al. Topical medication therapy for glaucoma and ocular hypertension
Negri et al. Timolol 0.1% in glaucomatous patients: efficacy, tolerance, and quality of life
CN103037857B (zh) 用于治疗/预防眼部炎性疾病的化合物
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
JP7716841B2 (ja) 黄斑変性症の新しい治療法
JP2021522180A5 (https=)
JP7299889B2 (ja) 緑内障を治療するためのＷｎｔ５ａの調節
CN110678193A (zh) 治疗和神经保护肽
Kaarniranta et al. Pharmacokinetics, efficacy, and safety of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in healthy volunteers: a phase I comparison vs. the corresponding preservative-free monotherapies
Bahrpeyma et al. Comprehensive pharmacokinetic evaluation of high melanin binder levofloxacin in rabbits shows potential of topical eye drops for posterior segment treatment
Qian et al. Inflammatory mechanisms in diabetic retinopathy: pathogenic roles and therapeutic perspectives
JP2015514760A5 (https=)
JP2025508127A5 (https=)
JP2022547231A5 (https=)
JP2022528566A5 (https=)
JP2022521273A5 (https=)
JP2020530459A5 (https=)
RU2314102C1 (ru) Способ комплексного лечения дисфункции мейбомиевых желез
RU2521337C1 (ru) Фармацевтическая композиция для лечения заболеваний глаз, связанных с нарушением метаболизма в тканях глаза и воспалительным поражением тканей глаза
Wang et al. Intravitreal injection of triamcinolone acetonide for macular edema due to retinitis pigmentosa and other retinal diseases
Edwards Acute Bacterial Tenonitis and Conjunctivitis following Intravitreal Injection
RU2559580C1 (ru) Препарат для лечения синдрома "сухого глаза"
RU2504372C1 (ru) Глазные капли
US20240108632A1 (en) Pharmaceutical composition for administration as ophthalmic drop to patient requiring optic nerve protection